Atrial natriuretic peptide levels in rheumatic mitral regurgitation and response to angiotensin-converting enzyme inhibitors

被引:0
|
作者
Kula, S
Tunaoglu, FS
Olgunturk, R
Gokcora, N
机构
[1] Gazi Univ, Dept Pediat Cardiol, Ankara, Turkey
[2] Gazi Univ, Dept Nucl Med, Ankara, Turkey
关键词
angiotensin-converting enzyme inhibitors; atrial natriuretic peptide; rheumatic mitral regurgitation;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Rheumatic mitral regurgitation (MR) causes heart failure by volume overload and an increase in atrial natriuretic peptide (ANP) levels by atrial stretching. Symptoms of heart failure improve with ANP treatment. Angiotensin-converting enzyme inhibitors (ACEI) and ANP have similar effects, such as vasodilation, natriuresis and diuresis. OBJECTIVE: To determine ANP levels and response to ACEI treatment in children with rheumatic MR. PATIENTS AND METHODS: Patients with rheumatic MR were divided into two groups: the digoxin group (10 girls, two boys; age range 10 to 18 years, mean 14 +/- 0.72 years; taking digoxin for at least one year) and the control group (eight girls, four boys; age range eight to 17 years, mean 13.5 +/- 0.81 years). None of the patients in either group had symptoms of heart failure. Serum ANP levels, left ventricular systolic functions, and mitral and aortic stroke volumes of both groups were evaluated on admission. The digoxin group was given ACEI and re-evaluated on the 20th day of treatment. RESULTS: At baseline, ANP levels were higher in the digoxin group (27.3 +/- 6.5 pg/100 muL) than in the control group (6.9 +/- 0.9 pg/100 muL) (P<0.05). On the 20th day of treatment, there were no significant differences in the ANP levels of the digoxin (13.2 +/- 6.1 pg/100 mu L) and control groups. There was a significant decrease in ANP levels in the digoxin group between baseline and the 20th day of therapy. Mitral stroke volumes (510.4 +/- 92.8 mL/m(2)) and left ventricular diastolic volume (108 +/- 12 mL/m(2)) in the digoxin group at baseline were higher than those in the control group (315.3 +/- 59.9 mL/m(2) and 82 6.5 mL/m(2), respectively) on admission; on the 20th day of treatment, there were no significant differences in these values. At baseline, aortic stroke volume in the digoxin and control groups were 86.9 +/- 59.1 and 82.9 +/- 28.3 mL/m(2), respectively (P>0.05). On the 20th day of therapy, the aortic stroke volume of digoxin group had increased to 104.7 +/- 70.1 mL/m(2), significantly higher than that of the control group. CONCLUSION: ANP levels are a good indicator of volume overload. ACEI should be introduced at an early stage of rheumatic MR because, even if patients are taking digoxin, their heart failure may progress silently.
引用
收藏
页码:405 / 408
页数:4
相关论文
共 50 条
  • [1] The Effect of Angiotensin-Converting Enzyme Inhibitors of Left Atrial Pressure in Dogs with Mitral Valve Regurgitation
    Ishikawa, T.
    Tanaka, R.
    Suzuki, S.
    Miyaishi, Y.
    Akagi, H.
    Iino, Y.
    Fukushima, R.
    Yamane, Y.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2010, 24 (02) : 342 - 347
  • [2] Serum angiotensin-converting enzyme and plasma atrial natriuretic peptide levels in hyperthyroid and hypothyroid rabbits
    Yegin, E
    Yigitoglu, MR
    Ari, Z
    Celik, I
    Akcay, F
    Suzek, H
    JAPANESE HEART JOURNAL, 1997, 38 (02): : 273 - 279
  • [3] Effectiveness of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker on atrial natriuretic peptide
    Sata, N
    Tanaka, Y
    Suzuki, S
    Kamimura, R
    Mifune, H
    Nakamura, K
    Miyahara, K
    Arima, T
    CIRCULATION JOURNAL, 2003, 67 (12) : 1053 - 1058
  • [4] Novel peptide inhibitors of angiotensin-converting enzyme 2
    Huang, LL
    Sexton, DJ
    Skogerson, K
    Devlin, M
    Smith, R
    Sanyal, I
    Parry, T
    Kent, R
    Enright, J
    Wu, QL
    Conley, G
    DeOliveira, D
    Morganelli, L
    Ducar, M
    Wescott, CR
    Ladner, RC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (18) : 15532 - 15540
  • [5] Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue
    Campbell, DJ
    Duncan, AM
    Kladis, A
    HYPERTENSION, 1999, 34 (02) : 171 - 175
  • [6] Angiotensin-Converting Enzyme Inhibitors
    Izzo, Joseph L., Jr.
    Weir, Matthew R.
    JOURNAL OF CLINICAL HYPERTENSION, 2011, 13 (09): : 667 - 675
  • [7] Angiotensin-converting enzyme inhibitors
    Brown, NJ
    Vaughan, DE
    CIRCULATION, 1998, 97 (14) : 1411 - 1420
  • [8] INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME
    CUSHMAN, DW
    ONDETTI, MA
    CHEMTECH, 1982, 12 (10) : 620 - 624
  • [9] Angiotensin-converting enzyme inhibitors
    Menard, J
    Patchett, AA
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56: DRUG DISCOVERY AND DESIGN, 2001, 56 : 13 - 75
  • [10] Role of angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation
    Finkielstein, D
    Schweitzer, P
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (06): : 734 - 736